Defective Pharmaceuticals: Tracing Links between Dangerous Drugs and Birth Defects

Defective Pharmaceuticals: Tracing Links between Dangerous Drugs and Birth Defects

Jul 11

The pharmaceutical industry plays an extremely vital role in finding ways to push health care and medical solutions. Without the innovations continuously offered by pharmaceutical companies and manufacturers, there will be little opportunities for medical professionals to find the best and most effective treatment plans to provide patients with the best outcomes. In an ideal world, progress in the pharmaceutical industry is constantly forward moving. However, reality paints a starkly different scenario. Sometimes, pharmaceutical companies commit missteps that can contribute to unwanted results.

Such is the case involving a number of dangerous drugs that have been found to lead to cases of birth defects. There are two drugs in particular that have been thrust into the national spotlight after some significant evidence gave credence to the devastating side effects they reportedly cause. One of the drugs in question is Depakote, which is a prescription drug meant to treat seizures and manic episodes in individuals with bipolar disorder. The other one is Zofran, an anti-nausea typically prescribed to pregnant women suffering from morning sickness

According to the website of Depakote lawsuit attorneys at Williams Kherkher, there have been several studies showing significant evidence that the drug used to treat seizures and mania can be particularly harmful for pregnant women and their unborn child. It seems that women who had taken Depakote in the duration of their pregnancy can give birth to babies suffering from a number of defects, including spina bifida and fetal valproate syndrome. They also point out that the Food and Drug Administration had issued a safety alert in 2013 regarding these concerns.

Concerns about similar dangers about the anti-nausea drug Zofran have also been raised. According to a study conducted through the Motherisk program lead by the Hospital for Sick Children in Canada, there seems to be plenty of ground for concerns regarding birth defects to be raised. The Motherisk study concludes that the concerns regarding links between Zofran and the occurrence of congenital heart defect and orofacial defects have merit. Several women who have found their children born with such conditions have sought reprieve through legal avenues, such as the mother of 2-year old Arianah Reisen.

A Zofran lawyer is probably all too aware of the grave effects taking some medications during pregnancy may have on the health and well-being of an unborn child.